论文部分内容阅读
虽然早在19世纪人们对促红细胞生成素(Epo)就有所认识,但至本世纪50年代才得以命名。自70年代从人尿中分离和纯化Epo以后,Epo研究取得了重大突破,包括放免测定、氨基酸序列分析及80年代中期用基因克隆生产出具有与天然Epo相同氨基酸结构及糖化的重组Epo(rHuEpo),由此,rHuEpo作为一种替代因子或药物应用于临床成为现实。1986年以来,大量的rHupo临床Ⅰ/Ⅱ期研究见诸报告,近年国内也有应用,不久的将来,rHuEpo的临床应用必
Although people knew about erythropoietin (Epo) as early as the 19th century, they were not named until the 1950s. Since the 1970s, Epo isolation and purification from human urine has led to major breakthroughs in Epo research, including radioimmunoassay, amino acid sequence analysis and gene cloning in the mid-1980s to produce recombinant Epo (rHuEpo) with the same amino acid structure as native Epo and glycation ), Thus, rHuEpo as a substitute factor or drug used in clinical reality. Since 1986, a large number of rHupo clinical Ⅰ / Ⅱ studies have been reported in recent years, there are also domestic applications, the near future, the clinical application of rHuEpo will